Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema

European Journal of Ophthalmology

Volumn 26, Issue 5, 2016, Pages 454-459

  Matonti, Frederic ^a,b   Pommier, Stephan ^b   Meyer, Franck ^b   Hajjar, Christian ^b   Merite, Pierre Yves ^b   Parrat, Eric ^b   Rouhette, Herve ^b   Rebollo, Olivier ^b   Guigou, Sebastien ^b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b P15 Network   (France)

Author keywords

Dexamethasone; Diabetic macular edema; Intravitreal injection; Macular edema; Optical coherence tomography; Ozurdex

Indexed keywords

DEXAMETHASONE; GLYCOSYLATED HEMOGLOBIN; TRIAMCINOLONE; VASCULOTROPIN; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CATARACT; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; DIABETIC MACULAR EDEMA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; INTRAVITREAL IMPLANT; KERATOPATHY; MUSCLE HYPERTONIA; OCULAR HYPERTONIA; PRIORITY JOURNAL; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; DIABETIC RETINOPATHY; DRUG EFFECTS; DRUG IMPLANT; FEMALE; INTRAOCULAR PRESSURE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TONOMETRY, OCULAR; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84984863522     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000787     Document Type: Article

References (15)

1. Campochiaro PA, Brown DM, Pearson A, et al; FAME Study Group. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626-635.e2.
2. Elman MJ, Aiello LP, Beck RW, et al; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6): 1064-1077.e35.
3. Boyer DS, Yoon YH, Belfort R Jr, et al; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914.
4. Haller JA, Kuppermann BD, Blumenkranz MS, et al; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol. 2010;128(3):289-296.
5. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231(3):141-146.
6. Guigou S, Pommier S, Meyer F, et al. Efficacy and Safety of Intravitreal Dexamethasone Implant in Patients with Diabetic Macular Edema. Ophthalmologica. 2015;233(3-4):169-175.
7. Matonti F, Meyer F, Guigou S, et al. Ozurdex in the management of the macular edema following retinal vein occlusion in clinical practice. Acta Ophthalmol. 2013;91(7):e584-e586.
8. Zhao M, Bousquet E, Valamanesh F, et al. Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina. Invest Ophthalmol Vis Sci. 2011;52(9):6340-6347.
9. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473-2481.
10. Moisseiev E, Regenbogen M, Rabinovitch T, Barak A, Loewenstein A, Goldstein M. Evaluation of pain during intravitreal Ozurdex injections vs. intravitreal bevacizumab injections. Eye (Lond). 2014;28(8):980-985.
11. Martin DF, Maguire MG, Fine SL, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neo-vascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
12. Torriglia A, Valamanesh F, Behar-Cohen F. On the retinal toxicity of intraocular glucocorticoids. Biochem Pharmacol. 2010; 80(12):1878-1886.
13. Grunwald JE, Daniel E, Huang J, et al; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(1): 150-161.
14. Lam WC, Albiani DA, Yoganathan P, et al. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol. 2015; 9:1255-1268.
15. Scaramuzzi M, Querques G, Spina CL, Lattanzio R, Bandello F. Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina. 2015;35(6):1216-1222.